Lead Product(s): Camelid antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 24, 2020
The grant supports rapid development of an oral SARS-CoV-2 treatment and preventative product candidates through FDA Investigational New Drug (IND) submission and initial engineering work for a large-scale cGMP manufacturing plant.
Lead Product(s): LMN-101
Therapeutic Area: Infections and Infectious Diseases Product Name: LMN-101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: WestRiver Management
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 01, 2020
The round brings Lumen’s total equity and non-dilutive investment to $68 million and will support continued advancement of Lumen’s three clinical programs for C. difficile, norovirus and traveler’s diarrhea.